Cost-effectiveness analysis of dostarlimab plus chemotherapy versus chemotherapy as first-line treatment of metastatic non-squamous non-small cell lung cancer.
New lung cancer combination therapy offers survival benefits, though healthcare systems should evaluate whether improved outcomes justify increased costs.
This study evaluates the cost-effectiveness of dostarlimab plus chemotherapy in contrast to chemotherapy as first-line treatment of metastatic non-small cell lung cancer (NSCLC) from the perspective of healthcare payers in the U. The anticipated expenditure for dostarlimab plus chemotherapy therapy exceeded the cost for chemotherapy alone therapy (366,887.
What the study was
- Study design
- Meta-analysis/Systematic Review
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Expert review of pharmacoeconomics & outcomes research
Why it surfaced
Cost-effectiveness meta-analysis of dostarlimab (PD-1 checkpoint inhibitor) + chemotherapy vs chemotherapy alone for endometrial cancer; systematic review design. Score=7/10.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.